Nitazoxanide in Patients With Ulcerative Colitis

Condition(s) studied

Investigational drug(s) / intervention(s)

Mesalamine: Mesalamine or 5-amino salicylic acid (5-ASA), plays a crucial role in the treatment of ulcerative colitis (UC). It is the first-line therapy for mild to moderate cases of UC and is considered a cornerstone in its management.

Nitazoxanide: Nitazoxanide is an FDA-approved oral medication used to treat protozoal infections and is also effective against metronidazole-resistant Clostridium difficile colitis.

Study summary

Ulcerative colitis (UC) is a chronic inflammatory bowel Disease (IBD) that primarily affects the rectum and colon. The severity and persistence of mucosal inflammation are associated with morbidity and mortality.

Eligibility

Primary outcome measure(s)

• change in partial mayo score. — 3 months
  One non-invasive clinical measure for determining the severity of UC is the PMS. The composite score is derived from three subcategories: stool frequency, rectal bleeding, and physician's general assessment. The total score falls between 0 and 9

Trial sites (1)

More Alexandria University trials in Egypt

Other trials for the same condition